期刊名称：MEDICAL ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Medical Oncology
|
Medical Oncology is a well-established, highly reputed international peer-reviewed journal featuring original papers and reviews dedicated to the study of those areas of oncology and hematology that are most relevant to clinical practice. The focus of the journal includes not only the biology, immunology, epidemiology, pathology, pathogenesis and genetics of malignant tumors, but also the widest coverage of clinical issues associated with the disease. Topics |
|
treated run the gamut from articles on the diagnosis, treatment and prevention of solid and hematologic tumors, to work on the psychological, social and economic aspects of cancer. The journal also features review articles on the practice of medical oncology, and brief case reports highlighting elements of clinical practice.
Medical Oncology communicates the results of clinical and experimental research in oncology and hematology, particularly with experimental therapeutics with the field of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies in oncology and hematology. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
Abstracted/Indexed in:
Cambridge Scientific Abstracts
Current Contents/Clinical Medicine
Research Alert
Science Citation Index
Index Medicus/MEDLINE
PUBMED
Excerpta Medica/EMBASE
Biological Abstracts/BIOSIS
AIDS & Cancer Research
Instructions to Authors
General
Peter H. Wiernik, MD
Director, Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA • Tel: 718-920-1113 • Fax: 718-920-1123 • Email: pwiernik@aol.com
Anders Osterborg, MD, PhD
Department of Oncology (Radiumhemmet), Karolinska
University Hospital Solna, SE-17176 Stockholm, Sweden Tel: +46 851773385 • Fax: +46 8 318327 • Email: anders.osterborg@karolinska.se
Scope
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly with experimental therapeutics with the field of immunotherapy and chemotherapy. It also provides state-of-the-art Reviews on clinical and experimental therapies in oncology and hematology. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
Submission of Manuscripts
Authors should submit their manu-scripts online. Electronic submission substantially reduces the edito-rial processing and reviewing times and shortens overall publication times. Please connect directly to the site http://medo.edmgr.com and upload all of your manuscript files following the instructions given on the screen.
Editorial Policy: All contributions and general correspondence regarding editorial matters should be addressed to the Editor and sent to the nearest editorial office. Manuscripts sent to the journal must represent original research. Reviews will also be considered. Manuscripts will be sent for anonymous review by at least two referees, who will either be members of the editorial board or others of similar standing in the field. Authors will be notified of acceptance, rejection, or the need for revision within 3 weeks. When a manuscript is returned to the corresponding author for revision, it should be returned to the Editor within 3 months, otherwise it may be considered withdrawn.
Copyright
Authors will be asked before publication to assign the world copyright of their manuscript to Humana Press. Therefore, all manuscripts submitted must be accompanied by a signed statement that the article is original, is not under consideration, or has not been published previously elsewhere, and its content has not been anticipated by an previous publication.
Reviews: Scholarly reviews of topics within the scope of MO will be considered for publication after peer-review. Please send a one-page letter of inquiry to an Editor before preparing your manuscript, to make sure that a similar review is not in preparation.
Manuscripts
Type manuscripts in English, double-spaced on one side of consecutively numbered pages, with 1- to 1.5-in. margins. Please subdivide the manuscript into the following sequence of sections: Title page, Abstract, Key Words (for indexing purposes), Introduction, Materials and methods, Results, Discussion, Acknowledgment, References, Tables, Figure legends. Full-length papers of over 45 pages (including tables and fi gures) are discouraged. Papers not following the indicated format may be returned.
Submission on Disk: Once accepted for publication, the fi nal version of the manuscript must be submitted on disk. The preferred electronic version of your manuscript is Microsoft Word, in Macintosh format. PC-prepared disks are also acceptable.
Manuscripts and electronic versions must match. Revised electronic versions cannot be submitted without a corresponding reprinted manuscript.
Title page/Keywords: The title should be as brief as possible with noabbreviations. Include each author’s surname and initials and completeaddresses in English, including department, institution, city with postalcode, and country (indicating clearly which author is at which address).A corresponding author should be indicated, with telephone and faxnumbers and e-mail address provided. Please also provide a runningtitle of not more than 50 characters, and 5 to 10 keywords using stan-dard MeSH-Medline subject headings for indexing purposes, Termsnot contained within the title are preferred.
Abstract: The second page of the manuscript should contain only anabstract in a single paragraph of not more than 250 words. Abbrevia-tions and reference citations should not be used.
Introduction: The introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible and never to exceed 1500 words.
References: References should follow the Vancouver format. In the text, they should appear as numbers starting at 1. At the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text. All authors should be quoted for papers with up to fi ve authors; for papers with more that five authors, the first author only should be quoted followed by et al.Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus/Medline. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such.
1 Clements R, Gravell IH. Radiological appearances of hydatid disease
in Wales. Postgrad Med J 1986; 62:167–173.2 Greenberger JS, Long-term hematopoietic cultures. In: Golde W (ed).Hematopoiesis. Churchill Livingstone: New York, 1984, pp 203–242.
Illustrations: All illustrations, including chemical structures, must be provided in professional-quality, finished form ready for direct reproduction without revision by us. Electronic version in Tiff or EPS format is acceptable, with an accompanying hard copy. Color art cannot
be accepted unless the author is willing to assume the additional costs involved in production; quotes will be given on request.
Tables: Tables should be typed on separate sheets and numbered
consecutively with Arabic numbers. Tables should be self-explana-tory and include a brief descriptive title. Footnotes to tables indicated by lower case letters are acceptable, but they should not contain extensive experimental detail.
Abbreviations: Abbreviations should be defined after their first mention in the text. except for the use of accepted abbreviations, such as SI symbols, which need not be defined. Use generic names when referring to drugs; trade names may be given in parentheses at first mention.
Funding
Authors are expected to disclose any commercial or other associations that might pose a conflict of interest in connection with submitted material. All funding sources supporting the work and institutional or corporate affiliations of the authors should be acknowledged.
Additional Information
For journal and online advertising information, please contact the Journals Marketing Manager:
Scott I. Marshall, Springer, 233 Spring Street, New York, NY 10013-1578 E-mail: scott.marshall@springer.com 1-212-620-8405 (voice) • 1-646-206-9343 (mobile) • 1-212-647-1898 (fax)
Editorial Board
Associate Editors
Jan Walewski, MD
Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland
Janice P. Dutcher, MD
New York Medical College, Bronx, NY
Ezzeldin M. Ibrahim, MD
International Medical Center, Jeddah, Saudi Arabia
Thomas Miale, MD
Allan Blair Cancer Center, University of Saskatchewan, Canada
Giuseppe Masucci, MD
Karolinska Hospital, Stockholm, Sweden
University of Tennessee Medical Center at Knoxville, Knoxville, TN
Editorial Board
K. C. Anderson, Boston, MA
J. Bartunkova, Prague, Czech Republic
J. F. Bishop, Camperdown, Australia
G. Bonadonna, Milan, Italy
F. Caligaris-Cappio, Torino, Italy
D. Catovsky, London, UK
M. Cazzola, Pavia, Italy
A. Choudhury, Stockholm, Sweden
M. Colovic, Belgrade, Serbia
A. Forastiere, Baltimore, MD
H. Hansen, Copenhagen, Denmark
R. Hast, Stockholm, Sweden
H. E. Johnsen, Herlev, Denmark
L. Kvols, Tampa, FL
H. Mellstedt, Stockholm, Sweden
B. Modan, Tel-Hashomer, Israel
A. Nagler, Jerusalem, Israel
M. R. Nowrousian, Essen, Germany
D. Petrylak, New York, NY
K. R. Rai, New Hyde Park, NY
Lorna Rodriguez-Rodriguez, New Brunswick, NJ
J. Ruckdeschel, Detroit, MI
J. F. San Miguel, Salamanca, Spain
E. Vellenga, Gronigen, The Netherlands
A. Waage, Trondheim, Norway
R. Weiner, New Orleans, LA
H. Zwierzina, Innsbruck, Austria
|
